

Current Radiopharmaceuticals

Volume 1, Number 3, September 2008

Contents

Targeted Alpha Particle Therapy

Guest Editors: Ganesan Vaidyanathan and Roy Larsen

Editorial	125
Commercial Availability of Alpha-Emitting Radionuclides for Medicine <i>D.R. Fisher</i>	127
Production of Alpha Emitters for Targeted Alpha Therapy <i>A. Morgenstern, K. Abbas, F. Bruchertseifer and C. Apostolidis</i>	135
[²¹¹At]Astatine-Labeled Compound Stability: Issues with Released [²¹¹At]Astatide and Development of Labeling Reagents to Increase Stability <i>D.S. Wilbur</i>	144
Astatine Radiopharmaceuticals: Prospects and Problems <i>G. Vaidyanathan and M.R. Zalutsky</i>	177
Experimental Targeted Therapy Using [²¹¹At]meta-Astatobenzylguanidine and Transfection of the Noradrenaline Transporter Gene <i>M. Boyd, A.G. McCluskey, A. Sorensen and R.J. Mairs</i>	197
Radium-223: From Radiochemical Development to Clinical Applications in Targeted Cancer Therapy <i>Ø.S. Bruland, T.J. Jonasdottir, D.R. Fisher and R.H. Larsen</i>	203
Targeted Alpha-Particle Therapy with ²²⁷Th-Labeled Antibodies <i>J. Dahle and R.H. Larsen</i>	209
Treatment of Diffuse-Type Gastric Cancer Cells Using ²¹³Bi-Radioimmunoconjugates In Vitro and In Vivo Following Intraperitoneal Dissemination <i>C. Seidl and R. Senekowitsch-Schmidtke</i>	215
Targeting EGFR and HER2 with ²¹¹At-Labeled Molecules: Unexpected and Expected Dose-Effect Relations in Cultured Tumor Cells <i>J. Carlsson, A.C. Steffen, A.L. Sundberg, M. Vikström, A. Orlova, L. Gedda, B. Stenerlow, H. Lundqvist and V. Tolmachev</i>	225
Radioimmunotherapy of Infection with ²¹³Bi-Labeled Antibodies <i>E. Dadachova</i>	234
New Directions for Clinical Trials of Targeted Alpha Therapy for Metastatic Melanoma <i>B.J. Allen, C. Raja, S.M.A. Rizvi, P. Graham and J.H. Kearsley</i>	240
Targeted α-Particle Therapy: A Clinical Overview <i>M. Salvatori, L. Indovina and L. Mansi</i>	251
